ADC Therapeutics
Lausanne
About ADC Therapeutics
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $1.0B
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nyse:ADCT
- Website: adctherapeutics.com
- Phone: +1 908-731-5556
Industries & Categories
Biopharma, Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/adc-therapeutics-150637 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.